The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Pharmacogenetics of Antidepressant Medication Intolerance
Abstract
OBJECTIVE: The authors sought to identify genetic markers for antidepressant medication intolerance. Genetic variation in drug metabolizing enzymes such as cytochrome P450 2D6 (CYP2D6) has been postulated to underlie antidepressant intolerance (pharmacokinetic effect). However, variation in genes encoding serotonin receptors could also explain antidepressant side effects (pharmacodynamic effect). METHOD: An 8-week, double-blind, randomized pharmacogenetic study compared the widely prescribed antidepressants paroxetine (a selective serotonin reuptake inhibitor [SSRI]) and mirtazapine (not an SSRI) in 246 elderly patients with major depression. Genotypes were determined for the 102 T/C single nucleotide polymorphism (SNP) in the serotonin 2A (5-HT(2A)) locus (HTR2A), previously associated with psychotropic medication treatment outcome. Oligonucleotide microarrays were used to extensively characterize variation in the CYP2D6 gene. Clinical outcomes included treatment discontinuations, adverse events, medication compliance, and change in mood. RESULTS: Survival analysis showed discontinuations due to paroxetine-induced side effects were strongly associated with the HTR2A C/C genotype. There was a significant linear relationship between the number of C alleles and the probability of discontinuation. Side effect severity in paroxetine-treated patients with the C/C genotype was also greater. In contrast, HTR2A 102 T/C genotype had no effect on mirtazapine side effects. CYP2D6 genotype did not predict treatment outcome for either medication. CONCLUSIONS: Pharmacodynamic differences among patients due to variant 5-HT(2A) receptors appear to be more important than pharmacokinetic variation in determining paroxetine intolerance. Pharmacogenetic markers may be useful in predicting antidepressant treatment outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1997) · Europe PMC (PubMed Central) · Cited by 973
Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422
Marez, D., Legrand, M., Sabbagh, N., Lo Guidice, J.-M., Spire, C., Lafitte, J.-J., Meyer, U. A., & Broly, F. (1997) · Pharmacogenetics · doi:10.1097/00008571-199706000-00004 · Cited by 380
Pharmacogenetic prediction of clozapine response
Arranz, M., Munro, J., Birkett, J., Bolonna, A., Mancama, D., Sodhi, M., Lesch, K., Meyer, J., Sham, P., Collier, D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02221-2 · Cited by 347
(1996) · PubMed · Cited by 328
Polesskaya, O. O., & Sokolov, B. P. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10173 · Cited by 277
Du, L., Bakish, D., Lapierre, Y. D., Ravindran, A. V., & Hrdina, P. D. (2000) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(20000207)96:1<56::aid-ajmg12>3.0.co;2-l · Cited by 232
Double-Blind, Randomized Comparison of Mirtazapine and Paroxetine in Elderly Depressed Patients
Schatzberg, A. F., Kremer, C., Rodrigues, H. E., & Murphy, G. M. (2002) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200209000-00007 · Cited by 215
Self-citationThe relationship between paroxetine and the sparteine oxidation polymorphism
Sindrup, S. H., Brøsen, K., Gram, L. F., Hallas, J., Skjelbo, E., Allen, A., Allen, G. D., Cooper, S. M., Mellows, G., Tasker, T. C. G., et al. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.23 · Cited by 205
Raimundo, S., Fischer, J., Eichelbaum, M., Griese, E.-U., Schwab, M., & Zanger, U. M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200010000-00001 · Cited by 189
Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia
Segman, R. H., Heresco‐Levy, U., Finkel, B., Goltser‐Dubner, T., Shalem, R., Schlafman, M., Dorevitch, A., Yakir, A., Greenberg, D. A., Lerner, A., et al. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000842 · Cited by 155
Double-Blind, Randomized Comparison of Mirtazapine and Paroxetine in Elderly Depressed Patients
Schatzberg, A. F. (2002) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.10.5.541 · Cited by 146
Self-citationBanes, A. K., Florian, J. A., & Watts, S. W. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35225-5 · Cited by 129
Joober, R., Benkelfat, C., Brisebois, K., Toulouse, A., Turecki, G., Lal, S., Bloom, D., Labelle, A., Lalonde, P., Fortin, D., et al. (1999) · PubMed · Cited by 128
Stürmer, E., Moltke, L. L., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12045-7 · Cited by 126
Serotonin-2 Receptors and Human Sleep Effect of a Selective Antagonist on EEG Power Spectra
Landolt, H., Meier, V., Burgess, H. J., Finelli, L. A., Cattelin, F., Achermann, P., & Borbély, A. A. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00052-4 · Cited by 112
Pontomedullary distribution of 5-HT2A receptor-like protein in the rat
Fay, R. A., & Kubin, L. K. (2000) · The Journal of Comparative Neurology · Cited by 109
Cravchik, A., & Goldman, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1105 · Cited by 104
Pharmacogenetics of antidepressants: clinical aspects
Bertilsson, I.-L., Dahl, M. L., & Tybring, G. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb05954.x · Cited by 96
Bosker, F. J., Klompmakers, A. A., & Westenberg, H. G. M. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00023-y · Cited by 78
Malagié, I., Deslandes, A., & Gardier, A. M. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00486-6 · Cited by 70
Murphy, G. M., Pollock, B. G., Kirshner, M. A., Pascoe, N., Cheuk, W., Mulsant, B. H., & Reynolds, C. F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00289-5 · Cited by 62
Self-citationPullar, I. A., Carney, S. L., Colvin, E. M., Lucaites, V. L., Nelson, D. L. G., & Wedley, S. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00728-7 · Cited by 50
Janssen, P., Prins, N. H., Meulemans, A. L., & Lefebvre, R. A. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704716 · Cited by 40
Cited by
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450
Serotonin Transporter: Gene, Genetic Disorders, and Pharmacogenetics
Murphy, D. L. (2004) · Molecular Interventions · doi:10.1124/mi.4.2.8 · Cited by 448
Metadata
- Authors
- Murphy, G. M., Kremer, C., Rodrigues, H. E., & Schatzberg, A. F.
- Venue
- American Journal of Psychiatry
- Published
- 2003-10-01
- Volume
- 160
- Issue
- 10
- Pages
- 1830-1835
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2136825478
- Cited by
- 283
- References
- 27
- FWCI
- 17.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.